Using the Cellminer database, we correlated KCTD5 expression with sensitivity to 263 FDA-approved drugs in 60 tumor cell lines; the nine drugs with the strongest correlations with KCTD5 expression were XL-147, SNS-314, quizartinib, vemurafenib, indibulin, PLX-4720, AFP464, aminoflavone, and rapamycin (Fig. 10C). The gene discussed is KCTD5; the disease is neoplasm.